San Francisco, CA – Today, following the recent federal court decision in Texas designed to pull Mifepristone from the U.S. market, Medicines360 CEO Tina Raine-Bennett, MD, MPH, released the following statement:
“Last week, a lone federal judge in Texas declared in Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration et al that the U.S. Food and Drug Administration’s (FDA) approval of mifepristone was unlawful. As a doctor, let me be clear: Mifepristone — one of two drugs used in medication abortion — has been shown for 20 years to be safe and effective. Alongside contraception, it is part of the full suite of reproductive healthcare that women in this country must have equitable access to – ensuring that they have control over their lives and their futures.
“At Medicines360, our work is driven by our deep commitment to advancing a better, more equitable future for all women. We are a nonprofit pharmaceutical company focused on providing low cost, effective, women’s health products that help women realize their full potential by accessing medicines they need — and that work also demands that we pay attention to and speak up about policies and decisions that could harm the women we serve.
“So while we are relieved that this decision is currently stayed, Mifepristone remains protected, and the Biden Administration plans to appeal in this case, I know we must stand up alongside women across this country to call this decision what it is: an unprecedented and deeply disturbing attack on science and on our rights.
“Our nonprofit mission is to close critical gaps in women’s healthcare, and ensure that women have access to the medicines and devices they need to live their best and fullest lives. Importantly, our work also addresses gaps for women who are disadvantaged and discriminated against in the healthcare system, the women this decision would disproportionately impact.
“As this case continues to work its way through our court system, we will continue to stand with women by working to expand access to affordable birth control options.”
Press Contact: Stacey Manley
Vice President, Communications & Marketing